Janux Therapeutics (JANX) Financial Statements & Analysis

Janux Therapeutics (JANX) Income Statement

Janux Therapeutics reported revenue of $10.00M in fiscal 2025 (fiscal year ended Dec 31, 2025), down 5.6% from $10.59M a year earlier. Janux Therapeutics posted a net loss of $113.63M, compared with a net loss of $68.99M a year earlier. Gross margin was 100.0% and operating margin -1576.7%. In the most recent quarter, Q2 fiscal 2026 (ended Jun 30, 2026), revenue was $10.27M.

Janux Therapeutics Income Statement Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Janux Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Revenue & Gross Profit
Revenue	10.00	10.59	8.08	8.61	3.64	0.00	0.00
Cost of Revenue	125.90	68.39	54.92	0.84	26.24	3.04	0.01
Gross Profit	10.00	10.59	8.08	7.77	-22.60	-3.04	-0.01
Operating Expenses
Research & Development	125.90	68.39	54.92	53.44	26.24	3.04	3.00
Selling, General & Administrative	41.77	41.05	26.14	22.26	10.33	1.80	0.77
Operating Expenses	167.67	109.44	81.06	74.86	36.57	1.80	3.77
Operating Income	-157.67	-98.85	-72.98	-67.09	-32.93	-4.84	-3.77
Other Income/Expense
Interest Income	44.04	29.85	14.69	4.03	0.26	0.21	0.23
Interest Expense	0.00	0.00	0.00	0.00	0.00	-0.21	0.23
Other Income/Expense	44.04	29.85	14.69	4.03	0.26	-1.94	-0.23
Income
Income Before Tax	-113.63	-68.99	-58.29	-63.06	-32.67	-6.78	-4.00
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Income	-113.63	-68.99	-58.29	-63.06	-32.67	-6.78	-4.24
Net Income - Continuous Operations	-113.63	-68.99	-58.29	-63.06	-32.67	-6.78	-4.24
Net Income - Discontinued Operations	-	-	-	-	-	-	-
EBITDA	-155.64	-96.79	-71.02	-62.22	-32.82	-4.83	-3.77
EBIT	-157.67	-98.85	-72.98	-67.09	-32.93	-4.84	-
Depreciation & Amortization	2.03	2.06	1.96	0.84	0.11	0.01	0.01
Earnings Per Share
Basic EPS	-2.00	-1.00	-1.00	-2.00	-1.00	-7.00	-
Diluted EPS	-2.00	-1.00	-1.00	-2.00	-1.00	-7.00	-
Basic Shares Outstanding	61.97	53.75	44.02	41.47	23.53	0.92	41.61
Diluted Shares Outstanding	61.97	53.75	44.02	41.47	23.53	0.92	41.61

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Janux Therapeutics Financial Statements

What was Janux Therapeutics's revenue in fiscal 2025?

Janux Therapeutics reported revenue of $10.00M in fiscal 2025 (fiscal year ended Dec 31, 2025). That was down 5.6% from $10.59M a year earlier.

Is Janux Therapeutics profitable?

No. Janux Therapeutics reported a net loss of $113.63M in fiscal 2025. In fiscal 2024 it lost $68.99M.

What is Janux Therapeutics's operating margin?

Janux Therapeutics's operating income was −$157.67M on revenue of $10.00M in fiscal 2025, an operating margin of -1576.7%, compared with -933.6% a year earlier.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition